Receptor in Medical Technology

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is located in areas of the brain involved in the ... such as the hypothalamus. Stimulation of this receptor is strongly associated with feeding behavior and ...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate ... to those achieved with first-generation androgen receptor antagonists." In vitro data recently ... of action is unlike that of the leading androgen receptor antagonist, bicalutamide. Specifically, MDV3100: ...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

... first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is located in areas of the brain involved in the ... such as the hypothalamus. Stimulation of this receptor is strongly associated with feeding behavior and ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... Efficacy of the Intestine-Specific Chemokine receptor Antagonist CCX282-B (Traficet-EN) in Treatment of ... disease. "Targeting the CCR9 chemokine receptor represents a new and highly specific approach to ... is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed ...

Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy

... new therapeutic target for aggressive hormone receptor negative breast cancer tumors. (Logo: ... Karmanos scientists tested 84 cases of hormone receptor negative human breast carcinomas and discovered ... expressed in 74 percent of those cases. Hormone receptor negative breast carcinoma is considered an ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... after Failing Treatment Either with a VEGF receptor Inhibitor or after Treatment with both a VEGF receptor Inhibitor and an mTOR Inhibitor NEW YORK, ... (PFS) in RCC patients who failed a prior VEGF receptor inhibitor (sunitinib or sorafenib). Safety of ...

Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women

... gene expression by gender status in estrogen receptor (ER) positive tumor specimens. As with female ... had higher mean expression of the hormone receptor genes, likely due to the different hormonal ... between the triple negative and hormone receptor positive groups, including genes for which ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... (NSCLC) patients who have epidermal growth factor receptor (EGFR) mutations.(2) "Lung cancer kills more ... dual inhibitor of the epidermal growth factor receptor (EGFR) and human epithelial receptor 2 (HER2) tyrosine kinases.(1) It is the first ...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

... countries to evaluate whether the angiotensin II receptor blocker (ARB) olmesartan medoxomil can prevent ... Angiotensin II is a hormone that interacts with a receptor on arterial blood vessels, which results in ... blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonizing the release ...

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

... injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug ... injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug ... hormone sensitive advanced prostate cancer. As a receptor antagonist, degarelix reversibly binds to the ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... in vitro and in vivo for activity in LHRH receptor over-expressing and multi-drug resistant ovarian ... As a negative control, the study utilized LHRH receptor negative SKOV-3 ovarian cancer cells. In in ... that EP-100 was fast-acting, destroying LHRH receptor over-expressing OVCAR-3 cells within an hour ...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

... for Ophena(TM) , a novel selective estrogen receptor modulator (SERM) for the treatment of vaginal ... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral ... in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential ...

Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes

... of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation ... RAD1901 RAD1901 is a novel selective estrogen receptor modulator (SERM) under development at Radius as a ... types of tissue, functioning as estrogen receptor agonists in some tissues and as ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The ... Another important result from the Thrombin receptor Antagonist Percutaneous Coronary Intervention ... exposed to a very potent stimulant (TRAP-thrombin receptor agonist peptide)," said Enrico Veltri, M.D., ...

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne

... and commercialization. Through enhancing androgen receptor protein degradation, ASC-J9(TM) represents the ... of action, which selectively enhances androgen receptor degradation (ARD) to reduce androgen activity. ... system, through reducing high levels of androgen receptor present in the sebaceous gland to lower sebum ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... is the Company's first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment ... whose actions are predominantly mediated by 5HT2A receptor antagonism is being developed for the treatment ...

Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

... Overexpression of the androgen receptor is believed to contribute to the progression of ... MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen ... by blocking nuclear translocation of the androgen receptor and DNA binding. About Medivation ...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

... that targets the glucose-dependent insulinotropic receptor (GDIR) for the treatment of type 2 diabetes. The ... About the Glucose-Dependent Insulinotropic receptor (GDIR) The GDIR is an orphan G protein-coupled receptor (GPCR), discovered by Arena. It is expressed in ...

Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention

... trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing ... clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent ... an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi-billion ...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

... from the FDA on November 20 as a thrombopoietin receptor treatment for patients with chronic ITP who have ... PROMACTA is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical ... Fibrosis: PROMACTA is a thrombopoietin (TPO) receptor agonist and ...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... PROMACTA is the first oral thrombopoietin (TPO) receptor agonist approved for adult patients with chronic ... PROMACTA is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical ... Fibrosis: PROMACTA is a thrombopoietin (TPO) receptor agonist and ...

Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia

... of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cognitive impairment associated with ... major studies evaluating a nicotinic alpha-7 receptor agonist in schizophrenia and we are pleased to ... nicotinic alpha-7 receptor, a highly specialized receptor found in the central nervous system. In a Phase ...

Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders

... direct acting, intravenous (IV) and oral ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent ... an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi-billion ...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

... ) TAK-285 and TAK-593 are receptor tyrosine kinase inhibitors. Non-clinical data ... efficacy in affecting the Epidermal Growth Factor receptor / Human Epidermal Growth Factor receptor (EGFR/HER) and Vascular Endothelial Growth ...

VAI Finding Could Lead to New Drugs for Anxiety, Depression

... and other conditions by targeting the cellular receptor that CRF binds to, but there are no drugs ... Chemistry. "There is a lot of interest in this receptor as a drug target, and we are the first ... depression, and related disorders. The hormone's receptor is a protein on the surface of a cell or in its ...

Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress

... using its proprietary Toll-like receptor 3 agonist, Poly IC-Poly Arginine (Poly-ICR), at ... a potent vaccine adjuvant targeting the Toll-like receptor 3 (TLR3) pathway. Data showed that Poly-ICR, in ... About Poly-ICR: Poly-ICR is a Toll-like receptor 3 (TLR3) agonist that when combined with a ...

Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness

... information on the company's second estrogen receptor beta selective drug candidate that will ... of action of the company's selective estrogen receptor (ER) beta drug candidate and explain the safety advantages of this more highly selective estrogen receptor modulator, VG101, when compared to the currently ...

Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis

... variations in the gene for IL-1 receptor antagonist were found to be strongly and ... found that common genetic variations in the IL-1 receptor antagonist gene were significantly more frequent ... variations in the genes for IL-1b, TNFa, and IL-1 receptor antagonist were significantly more frequent in ...

Agendia Launches TargetPrint(R) for Breast Cancer Patients

... the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor receptor 2 (HER2) in breast cancer tumor biopsies. ...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

... randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination ... to and activating the protein known as TRAIL receptor 1. Using genomic techniques, HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1 antibody was generated by ...

Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer

... to and activating the protein known as TRAIL receptor 1. Using genomic techniques, HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1 antibody was generated by ... for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP ...

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

... the utility of our focus on G protein-coupled receptor (GPCR) drug research and the general approach ... receptor. Serotonin activation of the 5-HT2A receptor on platelets and vascular smooth muscle is ... hyperplasia. By blocking activation of the 5-HT2A receptor on platelets and other cardiovascular tissues, ...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

... the company's lead AMPA/kainate-type glutamate receptor antagonist, tezampanel, demonstrated improvement ... is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for ... effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of ...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

... presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally ... Scientific Meeting in Boston, MA. In this receptor pharmacology study, MAP0004 stimulated receptors ... The Company presented a poster summarizing the receptor pharmacology data entitled "Improved ...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

... is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for ... effects. By acting at both the AMPA and kainate receptor site to competitively block the binding ... product candidates: two ionotropic glutamate receptor antagonists and two ...

Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease

... class of treatments for PAH known as endothelin receptor antagonists. Tracleer(R) is a dual antagonist as ... (PAH) Tracleer(R) is an oral dual endothelin receptor antagonist, which is currently licensed for the ... an orally available dual endothelin receptor antagonist, has been approved as a therapy for ...

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering

... that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a ... the growing evidence for the role of angiotensin receptor blockers in preventing or reversing vascular ... effect of ACE inhibitors or other angiotension II receptor blockers (ARBs) in the reversal of ...

Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta

... ) today announced results on the role of estrogen receptor beta in breast cancer growth regulation. The ... that risk. This study shows that estrogen receptor beta stops the growth of breast cancer cells by ... for drugs that selectively regulate estrogen receptor beta." The study was conducted by investigators ...

Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation

... native estrogen receptors, MF101, an estrogen receptor beta selective modulator, regulated calcium ... by the activation of estrogen receptor beta. MF101 demonstrated this selective ... 2 clinical trial, MF101, our selective estrogen receptor beta modulator, was effective in the treatment of ...

Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs

... different compounds. "Selective estrogen receptor modulators (SERMs) differ from estrogen in how ... estrogen modulators. The selectivity is based on receptor subtype regulation, agonist, antagonist effect, ... of co-regulatory proteins. Selective estrogen receptor modulators can be useful for many indications in ...